ClinicalTrials.gg
RecruitingNCT03096418Updated Jun 16, 2026Results posted

Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response

A Phase 4 interventional study of Paclitaxel in Breast Neoplasm Female, sponsored by University of Wisconsin, Madison. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by University of Wisconsin, Madison · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2017; still recruiting 9 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 373 studies testing paclitaxel in Breast Neoplasms — 40 open to participants now, 60 under way, 13 of them phase 3. Paclitaxel · Breast Neoplasms.

Planned enrollment
206th of 361
50 · median 60
Started
2017
with 9 others
Phase 4
10 of 373
5 open now
Primary completion
2027-06
later than 38 of 59 live
Registered
285th of 373
by date

Among the 373 studies testing paclitaxel in Breast Neoplasms, this one is the 206th largest by planned enrollment of the 361 interventional ones that give a count, is one of 10 that started in 2017, is one of 10 in phase 4, reaches primary completion later than 38 of the 59 other live ones, and was the 285th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

40 of the 373 studies testing paclitaxel in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

35 more — sign in →

By country, each count listing its studies:

All 40 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies testing paclitaxel in Breast Neoplasms, or all of them as a file.
02

Study summary

The hypothesis of this study is that paclitaxel levels increase chromosomal instability (CIN) in tumors and this is lethal to tumors that have pre-existing CIN. Treatment will be administered on an outpatient basis. Paclitaxel will be initiated as standard infusions on days 1, 8, and 15 of a 21-day cycle. Participants will continue with paclitaxel for cycles 2-4 prior to surgery.

Read the detailed description

Primary Objectives

  • To test if cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers.

Secondary Objectives

  • To identify patient-specific differences in tumor levels and distribution of paclitaxel at 20 hours after first dose and patient-specific differences in peripheral non-tumor tissue (skin or plasma) paclitaxel levels 20 ± 4 hours after first dose.
  • To determine if paclitaxel levels are higher at 20h after the 3rd dose than after the first dose, and if levels are higher at 20h after the 10th, 11th, or 12th dose than the 1st and 3rd dose.
  • Compare pre-existing versus post-treatment antimitotic effects at 20h after the 1st dose, 20h after the 3rd dose, and 20h after the 10th, 11th, or 12th dose.
  • Correlate drug levels and distribution with biomarkers including mitotic index, aneuploidy, chromosomal instability, and Ki67.
  • Correlate pathologic response and clinical response with biomarkers including mitotic index, aneuploidy, CIN and Ki67.
  • To test if CIN increases in patient tumors in response to paclitaxel and to evaluate the feasibility of these measurements by genomic analysis.

Initial Actual Primary and Study Completion Date registered as 8/16/2022 with 24 participants enrolled.

Per a Protocol Amendment dated 5/7/24, this study will re-open to enroll up to 50 participants. NCI funding and data sharing information added.

03

Conditions studied

  • Breast Neoplasm Female

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with pathologically demonstrated breast cancer
  • Patients must be candidates for paclitaxel chemotherapy by their treating oncologist. No other or commercial therapeutic agents may be given concurrently with the paclitaxel.
  • Patients must not have disease on staging work-up per institutional guidelines.
  • A formalin-fixed paraffin embedded tumor block (preferred) or unstained slides must be available from a prior of the primary tumor (preferred) or lymph node. A minimum of 8 slides must be available.
  • The primary tumor or lymph node must be readily biopsied by surgery or radiology teams.
  • The primary tumor must be measurable by an imaging modality prior to treatment. This imaging modality is to be repeated after completion of 4 cycles of paclitaxel and prior to surgery. Such imaging modalities may include ultrasound, CT, mammography, or MRI. MRI will be the preferred imaging modality if available because it has the highest accuracy and positive predictive value for predicting pathologic complete response.All imaging will be performed per standard of care at the discretion of the treating physicians.
  • Subjects may not have had prior systemic chemotherapy regimens administered for treatment of their current breast cancer. However, studies (window studies, for example) that are deemed non-therapeutic, including those that utilize agents that are not FDA approved for the treatment of the patient's current breast cancer, are permitted.
  • Patients must have adequate organ and marrow function as determined by the treating oncologist.
  • Patient must be willing to undergo additional biopsy of breast tumor or lymph node.
  • Patient must have the ability and willingness to sign a written document.
  • Women of (per institutional policy) must agree to use effective as discussed with treating oncologist for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to paclitaxel including to other drugs formulated in Cremophor(R) EL (polyoxyethylated castor oil).
  • Patients with known due to concern that chemotherapy may cause further and potential infectious complications.
  • Patients on non-aspirin anti-coagulation (Coumadin, heparins, or clopidogrel) or with documented bleeding disorders will be excluded due to risk of bleeding with .
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active severe infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, other requiring therapy or psychiatric illness/social situations that would limit compliance with study requirements as determined by treatment physician.
  • Pregnant women are excluded from this study because paclitaxel is a pregnancy category D drug and may cause deleterious effects to the fetus. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with paclitaxel, breastfeeding should be discontinued if the mother is enrolled in the trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Weekly Paclitaxel

    Paclitaxel 80 mg/m2 will be initiated as standard infusion on days 1, 8, 15 of a 21-day cycle. Participants will continue with paclitaxel 80 mg/m2 for cycles 2-4 prior to surgery.

    Drug: Paclitaxel

Interventions

  • Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.

    Also known as: Taxol

06

What researchers measure

Primary outcomes

  1. Response to Paclitaxel

    To test if high cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers. Response determined by the percent decrease in linear measurement of tumor size on the greatest dimension per RECIST-like criteria

    Time frame: Up to 3 months

Secondary outcomes

  1. Tumor Level Difference of Paclitaxel

    Identify patient-specific differences in tumor levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.

    Time frame: Up to 1 day

  2. Non-Tumor Level Difference of Paclitaxel

    Identify patient-specific differences in non-tumor (plasma) levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.

    Time frame: Up to 1 day

  3. Paclitaxel Levels

    Paclitaxel levels at the first dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing difference at two time points within the same patient with paired statistics.

    Time frame: Up to 79 days

  4. Antimitotic Effects

    Compare pre-existing versus post-treatment antimitotic effects at 20 hours after the 1st dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by tissue analysis of tumor samples with phospho-histone H3 and stains for spindle morphology to quantify mitotic index and mitotic characteristics at two time points using paired statistical analysis.

    Time frame: Up to 79 days

  5. Mitotic Index

    The mitotic index is a measure of cells arresting in mitosis, previously thought to be the major mechanism of taxol action. It is defined as the percentage of cells undergoing mitosis in a given population of cells. An elevated mitotic index indicates more cells are at this phase of the cell cycle at the time of sampling.

    Time frame: Baseline and 20 hours post-first dose

  6. Correlate Drug Levels With Aneuploidy of Tumor

    Correlate pathologic response and clinical response with biomarkers including aneuploidy

    Time frame: Up to 3 months

  7. Correlate Drug Levels With Chromosomal Instability of Tumor

    Correlate pathologic response and clinical response with biomarkers including CIN

    Time frame: Up to 3 months

  8. Ki67 of Tumor

    The Ki-67 protein is a cellular marker for proliferation. Ki-67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 labeling index) is often correlated with the clinical course of cancer.

    Time frame: Up to 3 months

  9. Change in CIN Levels

    There are many proposed ways to measure CIN. Here, we used # of multipolar spindles as a surrogate of CIN measures.

    Time frame: Baseline and 20 hours post-first dose

07

Results

Posted Oct 13, 2023

Participant flow

Participant flow — Overall Study
MilestoneWeekly Paclitaxel
Started24
Paclitaxel concentration determine15
Analyzed after first dose16
Analyzed after third dose5
Analyzed after twelfth dose1
Completed24
Not completed0

Outcome measures

PrimaryResponse to Paclitaxel

To test if high cancers with high chromosomal instability (CIN) respond to paclitaxel better than low CIN cancers. Response determined by the percent decrease in linear measurement of tumor size on the greatest dimension per RECIST-like criteria

Time frame:
Up to 3 months
Reported as:
Mean · percent decrease in tumor size
Response to Paclitaxel
percent decrease in tumor sizeWeekly Paclitaxel
Response to Paclitaxel-29.63 (-70.21 to 30)
SecondaryTumor Level Difference of Paclitaxel

Identify patient-specific differences in tumor levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.

Time frame:
Up to 1 day
Reported as:
Number · micromolar
Tumor Level Difference of Paclitaxel
micromolarWeekly Paclitaxel
Participant 11.07
Participant 20.34
Participant 30.80
Participant 40.57
Participant 63.43
Participant 71.55
Participant 80.53
Participant 90.63
Participant 110.57
Participant 131.67
Participant 140.52
Participant 151.20
Participant 5NA
Participant 12NA
SecondaryNon-Tumor Level Difference of Paclitaxel

Identify patient-specific differences in non-tumor (plasma) levels of paclitaxel at 20 hours after first dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing variability between patients with descriptive statistics.

Time frame:
Up to 1 day
Reported as:
Number · micromolar
Non-Tumor Level Difference of Paclitaxel
micromolarWeekly Paclitaxel
Participant 10.023
Participant 20.040
Participant 30.030
Participant 40.027
Participant 50.031
Participant 60.020
Participant 70.013
Participant 80.011
Participant 90.020
Participant 110.038
Participant 120.040
Participant 130.094
Participant 140.048
Participant 150.035
SecondaryPaclitaxel Levels

Paclitaxel levels at the first dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by high-performance liquid chromatography of tumor and plasma samples and comparing difference at two time points within the same patient with paired statistics.

Time frame:
Up to 79 days
Reported as:
Mean · micromolars
Paclitaxel Levels
micromolarsWeekly Paclitaxel
First dose plasma paclitaxel0.041 (0.014 to 0.094)
Third dose plasma paclitaxel0.029 (0.013 to 0.062)
First dose intratumoral paclitaxel0.785 (0.34 to 1.67)
Third dose intratumoral paclitaxel1.21 (0.12 to 2.40)
SecondaryAntimitotic Effects

Compare pre-existing versus post-treatment antimitotic effects at 20 hours after the 1st dose, 20 hours after the 3rd dose, and 20 hours after the 12th dose. This is measured by tissue analysis of tumor samples with phospho-histone H3 and stains for spindle morphology to quantify mitotic index and mitotic characteristics at two time points using paired statistical analysis.

Time frame:
Up to 79 days
Reported as:
Number · number of mitotic cells
Antimitotic Effects
number of mitotic cellsWeekly Paclitaxel - BaselineWeekly Paclitaxel - 20 Hours After First DoseWeekly Paclitaxel - 20 Hours After Third DoseWeekly Paclitaxel - 20 Hours After Twelfth Dose
Participant 1113109——
Participant 24110032—
Participant 3100104105—
Participant 4101103——
Participant 6106108——
Participant 779103——
Participant 87527——
Participant 93563——
Participant 11611——
Participant 122430——
Participant 13106110101—
Participant 148610220—
Participant 15116101——
Participant 16106104——
Participant 1842214238
Participant 193070——
SecondaryMitotic Index

The mitotic index is a measure of cells arresting in mitosis, previously thought to be the major mechanism of taxol action. It is defined as the percentage of cells undergoing mitosis in a given population of cells. An elevated mitotic index indicates more cells are at this phase of the cell cycle at the time of sampling.

Time frame:
Baseline and 20 hours post-first dose
Reported as:
Number · mitotic index
Mitotic Index
mitotic indexWeekly Paclitaxel - Pre-treatmentWeekly Paclitaxel - 20 Hours Post-first Dose
Participant 11.42.6
Participant 213.379722
Participant 31.354.4
Participant 41.83.192745
Participant 61.0527652.305837
Participant 71.23.201638
Participant 80.61.29731
Participant 91.4666671.872558
Participant 110.1983110.32
Participant 120.321.44
Participant 1324.2
Participant 141.482.87
Participant 151.335.56
SecondaryCorrelate Drug Levels With Aneuploidy of Tumor

Correlate pathologic response and clinical response with biomarkers including aneuploidy

Time frame:
Up to 3 months

No measurements were reported for this outcome.

SecondaryCorrelate Drug Levels With Chromosomal Instability of Tumor

Correlate pathologic response and clinical response with biomarkers including CIN

Time frame:
Up to 3 months

No measurements were reported for this outcome.

SecondaryKi67 of Tumor

The Ki-67 protein is a cellular marker for proliferation. Ki-67 is an excellent marker to determine the growth fraction of a given cell population. The fraction of Ki-67-positive tumor cells (the Ki-67 labeling index) is often correlated with the clinical course of cancer.

Time frame:
Up to 3 months
Reported as:
Number · Percentage of Ki67 + cells
Ki67 of Tumor
Percentage of Ki67 + cellsWeekly Paclitaxel
Participant 190
Participant 280
Participant 390
Participant 645
Participant 790
Participant 860
Participant 915
Participant 1120
Participant 1225
Participant 1390
Participant 1460
Participant 1560
SecondaryChange in CIN Levels

There are many proposed ways to measure CIN. Here, we used # of multipolar spindles as a surrogate of CIN measures.

Time frame:
Baseline and 20 hours post-first dose
Reported as:
Number · % of cells with multipolar spindles
Change in CIN Levels
% of cells with multipolar spindlesWeekly Paclitaxel Pre-treatmentWeekly Paclitaxel - 20 Hours After First Dose
Participant 17.0851.38
Participant 22.4449
Participant 32.4426.92
Participant 43.9603960429.12621359
Participant 616.9811320860.18518519
Participant 73.79746835464.0776699
Participant 85.3333333362.96296296
Participant 98.57142857161.9047619
Participant 11027.27
Participant 124.256.6
Participant 135.664.5
Participant 1413.9558.82
Participant 153.4560.4

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Weekly Paclitaxel0/24 (0%)0/24 (0%)0/24 (0%)

Baseline characteristics

Age, Customized
Age, Customized(Participants)Weekly Paclitaxel
20-29 years1
30-39 years4
40-49 years7
50-59 years7
60-69 years2
70-79 years3
Sex: Female, Male
Sex: Female, Male(Participants)Weekly Paclitaxel
Female24
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Weekly Paclitaxel
Hispanic or Latino0
Not Hispanic or Latino24
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Weekly Paclitaxel
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American2
White22
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Weekly Paclitaxel
United States24
08

Study locations

2 of 2 sites recruiting
09

References and documents

Publications

  • Scribano CM, Wan J, Esbona K, Tucker JB, Lasek A, Zhou AS, Zasadil LM, Molini R, Fitzgerald J, Lager AM, Laffin JJ, Correia-Staudt K, Wisinski KB, Tevaarwerk AJ, O'Regan R, McGregor SM, Fowler AM, Chappell RJ, Bugni TS, Burkard ME, Weaver BA. Chromosomal instability sensitizes patient breast tumors to multipolar divisions induced by paclitaxel. Sci Transl Med. 2021 Sep 8;13(610):eabd4811. doi: 10.1126/scitranslmed.abd4811. Epub 2021 Sep 8. PubMed 34516829 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2017 (actual). Primary completion is estimated for Jun 2027, 123 months after the start.

Of 110 non-industry phase 4 interventional studies under Breast Neoplasms, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 64. This study's planned 123 months is above that.

Counting every sponsor, half of 130 studies reached it within 42 months; a quarter within 20 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2017
First posted
Mar 30, 2017
StartActual
Mar 13, 2017
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Results first posted
Oct 13, 2023
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03096418
Responsible party
Sponsor
First posted
Mar 30, 2017
Start date
Mar 13, 2017
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Results posted
Oct 13, 2023
Last update
Jun 16, 2026

Study contacts

Cancer Connect
Contact
clinicaltrials@cancer.wisc.edu
800-622-8922
Marina Sharifi, MD, PhD
principal investigator · University of Wisconsin, Madison

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion